An exploratory, randomized, crossover MRI study of microbicide delivery with the SILCS diaphragm compared to a vaginal applicator.
BACKGROUND
Microbicide gels studied for HIV prevention often are delivered via a single-use vaginal applicator. Using a contraceptive diaphragm such as the SILCS diaphragm for gel delivery could have advantages, including lower cost and additional pregnancy prevention.


METHODS
We performed an exploratory, nonblinded, randomized, crossover study among healthy, sexually active, nonpregnant women. Using BufferGel, we evaluated three microbicide delivery methods for gel distribution and retention: SILCS single-sided gel delivery, SILCS double-sided gel delivery and a vaginal applicator (without SILCS). Magnetic resonance images were taken at baseline, after gel insertion, and immediately and 6 h after simulated intercourse. Three women completed all gel delivery methods described in this article.


RESULTS
Magnetic resonance imaging analysis indicated similar gel spread in the vagina among all three methods. SILCS single-sided gel application resulted in the most consistent longitudinal coverage; SILCS double-sided gel application was the most consistent in the transverse dimension.


CONCLUSIONS
Gel coverage was similar with all three methods. These results suggest that the SILCS microbicide delivery system is comparable to vaginal applicators for delivery of gel products intravaginally.
University of Pennsylvania, Philadelphia, PA 19104, USA.
Sara
S
Pentlicky
Mark
M
Rosen
Patricia S
PS
Coffey
M
M
Kilbourne-Brook
A
A
Shaunik
Courtney A
CA
Schreiber
Kurt
K
Barnhart
D000282:Administration, Intravaginal; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D003075:Coitus; D003274:Contraceptive Devices, Female; D018592:Cross-Over Studies; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods; D005260:Female; D005782:Gels; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D008279:Magnetic Resonance Imaging; D011247:Pregnancy; D016896:Treatment Outcome; D055815:Young Adult
D000890:Anti-Infective Agents; D005782:Gels